Citi Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO)

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Bausch + Lomb Corporation, with a price target of $21.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Wuensch is a 4-star analyst with an average return of 2.3% and a 50.93% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and GE Healthcare Technologies Inc.

In addition to Citi, Bausch + Lomb Corporation also received a Buy from TipRanks – Google’s Google Medical – Instruments and Supplies in a report issued on March 31. However, yesterday, Evercore ISI maintained a Hold rating on Bausch + Lomb Corporation (NYSE: BLCO).

Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.41 billion and a GAAP net loss of $58 million. In comparison, last year the company earned a revenue of $1.28 billion and had a GAAP net loss of $3 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Last month, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.